Survey of fertility preservation options available to patients with cancer around the globe by Rashedi, Alexandra S. et al.
original
reports
Survey of Fertility Preservation Options Available
to Patients With Cancer Around the Globe
Alexandra S. Rashedi1; Saskia F. de Roo2; Lauren M. Ataman1; Maxwell E. Edmonds1; Adelino Amaral Silva3; Anibal Scarella4;
Anna Horbaczewska5; Antoinette Anazodo6; Ayse Arvas7; Bruno Ramalho de Carvalho8; Cassio Sartorio9; Catharina C.M. Beerendonk2;
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abstract
PURPOSE Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-
preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are
fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale.
METHODS Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global
Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure
trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that
provide oncofertility services.
RESULTS Sixty-three responses were received (response rate, 25%), and 40 were analyzed from oncofertility
centers in 28 countries. Thirty of 40 survey results (75%) showed that formal referral processes and psy-
chological care are provided to patients at the majority of sites. Fourteen of 23 respondents (61%) stated that
some fertility preservation services are not offered because of cultural and legal barriers. The growth of
oncofertility and its capacity to improve the lives of cancer survivors around the globe relies on concentrated
efforts to increase awareness, promote collaboration, share best practices, and advocate for research funding.
CONCLUSION This survey reveals global and regional successes and challenges and provides insight into what is
needed to advance the field and make the discussion of fertility preservation and endocrine health a standard
component of the cancer treatment plan. As the field of oncofertility continues to develop around the globe,
regular assessment of both international and regional barriers to quality care must continue to guide process
improvements.
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INTRODUCTION
The primary goal of oncofertility is to increase access for
patients with cancer to fertility counseling and fertility
preservation options to improve the overall quality of life
of cancer survivors.1,2 As the field of oncofertility ex-
pands, a need exists to clarify the oncofertility services
that are provided on a global scale and to define the
challenges faced by providers and patients. Current
barriers represent areas for improvement in this growing
field and can be addressed through collaboration with
professional societies and governments. For these
reasons, we conducted a global oncofertility resource
assessment survey to document the experiences of
existing oncofertility centers within the Oncofertility
Consortium (OC) Global Partners Network.
METHODS
Survey Design
A survey was sent to members of the OC Global
Partners Network and international experts in the field
to collect information about the fertility preservation
services offered to patients with cancer and the bar-
riers to oncofertility care at their centers. The survey
was written in English because all potential partici-
pants were English speaking. Invited study partici-
pants were clinicians, researchers, nurses, patient
navigators, and psychologists. A pilot survey was
generated for attendees of the 2015 Oncofertility
Conference and after cognitive debriefing, was sub-
sequently converted to an electronic format through
the use of SurveyMonkey software. The final version
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was e-mailed to 191 contacts of the OC Global Partners
Network. The Northwestern University institutional review
board determined that the study did not constitute research
that involves human subjects; therefore, additional in-
stitutional review board review and approval was not
required.
Survey Inclusion/Exclusion
Upon receipt of multiple responses from the same center,
scores were averaged to generate mean values. All open-
ended response data provided by the study participants are
reported in the results. Surveys were excluded from the
analysis if respondents did not provide contact or identi-
fication information, if the survey was left blank, or if du-
plicate responses were submitted. Appendix Table A1
lists the countries and organizations that participated in
the study.
Survey Questions
Respondents were asked a total of 12 questions about
organization of referrals, patient access to medical pro-
fessionals, barriers and challenges faced at centers, and
estimated reimbursement of oncologic fertility preservation
by governmental entities or insurance companies (Ap-
pendix Table A2). Six questions were dichotomous (yes/
no), with space provided for open-ended comments
(questions 1, 2, 3, 6, 10, and 11). Three questions were
multiple choice, where only one answer could be selected
(questions 7, 8, and 9). Two questions were multiple re-
sponse where respondents could select one or more
answers (questions 5 and 12). One question contained
a matrix of drop-down menus where respondents could
select whether a fertility preservation service is offered
to specific age ranges of female and male patients
(question 4).
Analysis of Survey Results
Survey responses were exported to Microsoft Excel software
(Microsoft Corporation, Redmond, WA). The dichotomous
and multiple response questions were coded with nu-
merical values (yes = 1, no = 2) to facilitate statistical
analysis. Graphs were generated with both SPSS for Win-
dows version 23.0 (IBM Corporation, Armonk, NY) and
Microsoft Excel software. Descriptive statistics were used to
analyze the quantitative data. Two individuals who were
blinded to the region analyzed written responses.
RESULTS
A total of 63 responses were received (response rate, 25%),
and of those, 47 were valid, which resulted in the inclusion
of 40 centers after combining multiple responses from the
same center. Appendix Table A1 lists the participating
centers by country and continent. Appendix Table A3 lists
the frequencies and percentages of responses to di-
chotomous (yes/no) questions. The denominator for each
survey question changed according to the number of
responses because not all respondents opted to answer
each question.
Organization of Referrals
In terms of organizational structure, 30 of 40 respondents
(75%) reported having an established referral system at
their site, and 35 of 40 (88%) reported having a patient
registry. The largest group of respondents, 14 of 37 (38%),
indicated that the average length of time at their center
between cancer diagnosis and fertility preservation con-
sultation is 1 to 2 days. Nine of 37 respondents (24%)
reported that the time between consultation and fertility
preservation procedures was 1 to 2 days; nine of 37 (24%)
also reported the time to be 3 to 5 days between consul-
tation and fertility preservation procedures. Eleven of 36
(31%) indicated the time between fertility preservation and
cancer treatment was 3 to 5 days. (Appendix Table A4).
Respondents reported a variety of referral processes. Some
centers see patients with cancer for fertility preservation
counseling within 24 hours of diagnosis, such as at the IVF
Centro de Reproducción in Panama and at the Seoul
National University Bundang Hospital in South Korea; two
sites specified that the referral from cancer diagnosis to
fertility consultation can take ≥ 3 weeks.
As indicated in the open-ended survey responses, oncol-
ogists refer their patients at the majority of centers (16 of
19). However, at the Centro de Preservação da Fertilidade
in Portugal, Huntington Medicina Reprodutiva in Brazil,
andMcGill University Health Centre Reproductive Centre in
Canada, patients may set up their own appointments. The
Seoul National University Bundang Hospital attributed
referral challenges to discrepancies between the policies
that govern oncologists and reproductive physicians. At the
Royal Children’s Hospital in Melbourne, Australia, the
development of written informational support, clear referral
pathways, and fertility preservation management protocols
within the pediatric setting have doubled the rate of fertility
counseling since 2013. The Clinic of Endocrinological
Gynecology at the Jagiellonian University Medical College
in Poland noted time burden and a lack of awareness
among clinicians as its two greatest barriers to care.
Patient Access to Specialized Professionals
Nine of 34 respondents (26%) reported having a nurse
navigator, social worker, or specific oncofertility patient
navigator for patients with cancer of reproductive age. At
the Ceará Blood Center in Fortaleza, Brazil, an oncology
nurse navigator (a registered nurse with oncology-specific
knowledge) offers individualized assistance to patients and
their families. This patient navigator provides the education
and resources necessary to expedite stressful decision
making for the patient and ensures timely access to quality
health and psychosocial care.
With regard to patient counseling, 30 of 40 respondents
(75%) provide routine psychological support to patients.
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At the Centre for Fertility Preservation at the Coimbra
Hospital and University Centre in Portugal, a psychologist
specializes in helping patients through fertility preservation
decision making after a cancer diagnosis. If the patient
ultimately decides to undergo a procedure, the psychologist
provides support throughout the entirety of the fertility
preservation process by gauging the patient’s mental
condition and emotional state.
Services Offered at the Initial Fertility
Preservation Consultation
Thirty seven of 40 survey respondents (93%) identified the
services offered to patients at their facilities. For pediatric
males and females, the services most commonly offered
are testicular tissue cryopreservation (n = 16) and ovar-
ian tissue cryopreservation (n = 26), respectively. For
adolescent males and females, sperm cryopreservation
(n = 34) and egg cryopreservation (n = 26) and ovarian
tissue cryopreservation (n = 28) are available options.
In the adult age category, more third-party options were
discussed with both males and females, including
adoption (n = 29) and donation of eggs (n = 23), sperm
(n = 25), and embryos (n = 28). Of the 40 respondents,
only one stated that gestational surrogacy is mentioned as
a future possible consideration to pediatric females; six
reported mentioning gestational surrogacy to adolescent
females, and 18 reported mentioning the option to adult
females (Fig 1).
Barriers and Challenges
The majority of respondents, 37 of 40 (93%), identified
barriers to care (Table 1). Fourteen of 23 respondents
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FIG 1. Fertility preservation services offered to patients at survey respondent organizations. (A) Pediatric patients. (B) Ad-
olescent patients. (C) Adult patients.
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(61%) identified religious or cultural restrictions to onco-
fertility care offered at their sites. However, lack of in-
surance coverage and significant financial burden to
patients were identified most often (both 62%; 23 of 37).
In addition, 9 of 37 respondents (24%) indicated a lack of
providers as a challenge their center faces. In Brazil,
physicians’ resistance to discuss fertility issues may be one
of the greatest challenges, above even the high estimated
costs noted (Table 2).
Eleven of 37 respondents (30%) stated that the costs of
fertility preservation procedures are covered by insurance
or national or provincial health systems, whereas 26 of 37
respondents, more than two thirds (70%), reported that
costs are not covered (Appendix Table A3). The highest
costs of oncofertility care were noted in Japan. In Gifu,
oncofertility procedure costs were reported to be as high as
5,000 US dollars (USD) per patient for ovarian tissue
cryopreservation, with sperm cryopreservation costing only
approximately 150 USD and egg and embryo cryopreser-
vation costing from 2,500 to 3,500 USD per patient. Re-
spondents from St Mariana University in Kawasaki reported
even higher costs for oncofertility procedures, which range
from 6,000 to 8,000 USD. In contrast, at the Radboud
University Medical Center in the Netherlands, all fertility
preservation options are reimbursed by insurance or the
hospital (Table 2).
The survey responses indicated various legal challenges
about specific procedures. One notable cultural and legal
barrier to oncofertility care was related to the use of sur-
rogacy. This topic is explored in the accompanying article.4
DISCUSSION
In this study, we found global trends in the services offered
to pediatric, adolescent, and young adult patients with
cancer, including some notable regional differences, and
learned more about challenges and barriers to care. The
information gathered in this analysis would be stronger with
a higher response rate and a field-wide study population.
The OC Global Partners Network was recently founded in
2013, so the survey respondents were limited to the current
members of the group at the time of this study. This cohort
of professionals was selected because of their declared
commitment to the field of oncofertility and ease of contact.
However, it is important to recognize that those surveyed
are considered leaders in oncofertility care, and as a result,
the findings may highlight the most successful settings. An
online survey and the existence of language barriers could
have contributed to the relatively low response rate, although
the response rate is comparable to other clinical surveys.5
An oncofertility consult ideally occurs in the short window of
time between a cancer diagnosis and the start of treatment.
A major goal of the field is for this conversation to become
routine practice in cancer treatment.6 Timely referral of
a patient with a new diagnosis by an oncologist to a re-
productive endocrinologist is vital and requires an effective
connection between the two medical specialists. Stud-
ies show that fewer than one half of reproductive-age
patients who undergo cancer treatment are referred to
endocrinology specialists despite recommendations from
ASCO;7 this is due to a combination of factors, including
a lack of knowledge among oncologists, a hesitance of
patients to bring up their desire to preserve their fertility,
and the inability to delay treatment of aggressive cancers.8
As a result of these obstacles, patient navigators9 and
established referral processes are critical to ensure patients
receive the best and most efficient fertility preservation care
possible. The current results are consistent with this observed
disconnect, with only one quarter of survey respondents
reporting the use of specialized oncofertility navigators.
In addition, national registries are ideal for collecting pop-
ulation data, which can be useful for evaluating the success
of fertility preservation referrals. The majority of centers in-
cluded in this study confirmed that they have established
oncofertility registries. In 2015, the Fertility Understanding
Through Registry and Evaluation (FUTURE) research group
launched the first Web- and population-based national
oncofertility registry in Australia and New Zealand.10 These
databases track patient-specific information, including de-
mographic details, cancer stage, and fertility-related issues
as a result of cancer or its treatment.11 FUTURE is expected
to be a leading model for other countries to highlight their
own systems’ assets as well as to identify their unmet needs.
The American Society for Reproductive Medicine and ASCO
recommend that psychological counseling be offered before
cancer treatment.12,13 Ready access to a psychologist during
the fertility preservation counseling process has been shown
to help to reduce patient anxiety as well as enhance com-
munication between relevant medical professionals because
the patient’s individual needs are more readily identified.14
Moreover, a marked reduction in anxiety and depression is
seen in patients who receive structured cognitive behavioral
counseling.15 Specialized counseling is associated with
higher quality-of-life indications and less regret.1 The fact that
30 of 40 (75%) of the oncofertility centers surveyed provide
formal psychological counseling to patients with cancer is
encouraging.
The ability to have one’s own biologic children is a priority to
patients with cancer, and fertility loss can be a source of
significant distress.15 ASCO published updated guidelines
in 2013 that recommend that oncologists discuss fertility
preservation options with patients at risk for infertility as
a result of their treatment.8 Resistance among oncologists
to discuss fertility issues may be due to physicians’ desire to
treat cancers as quickly as possible and to prioritize dis-
cussions about cancer therapy and management. Studies
have found that when the prognosis is poor, oncologists are
less likely to refer patients to reproductive endocrinology
specialists or to bring up fertility discussions at all.8 Phy-
sician reluctance to discuss fertility could also be due to
a lack of awareness of oncofertility developments, a lack of
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TABLE 2. Regional Estimates of the Potential Out-of-Pocket Financial Burden of Fertility Preservation Procedures for Patients With Cancer
Continent and Country Coverage of Fertility Preservation Procedures Rank of Cost to Patient
Africa
Egypt No coverage. Some centers at university hospitals may offer lower-cost services, and
charities support patients with fewer resources. In general, the cost of a single cycle of
IVF/ICSI is between 500 and 1,000 USD.
$$
Tunisia Insurance coverage applies only for couples with demonstrated infertility. Patients must
pay for gonadotropins, which often are expensive. Costs for procedures are low and
vary from 80 to 135 USD depending on the procedure.
$-$$$
Asia
China Patients pay out-of-pocket, but the cost tends to be approximately 270 USD. $$
India Fertility preservation procedures are not covered by insurance. Patients must pay
themselves. Tissue storage costs are, in some cases, covered by in-house funding or
grants.
$$$$
Iran (Islamic Republic of) Partial insurance coverage for ART procedures. Only counseling and preliminary tests
are typically covered. However, operations and other fertility preservation techniques
often are thoroughly covered by insurance, such as ovarian transposition, ovarian
transplantation, and laparoscopic surgery for ovarian tissue retrieval, especially in
government hospitals. However, larger insurance companies provide various
treatment insurance so that patients may afford hospital expenses and even pay no
money in many cases where infertility is a factor, but ART treatment is still an
exception to this.
$$-$$$
Japan Patients pay out-of-pocket (including for consultations) because insurance does not
cover cryopreservation procedures, which can cost from 150 to 8,000 USD. Some
municipal or prefectural governments just started financial reimbursement for fertility
preservation treatment, but this is still not common.
$-$$$$
Korea (Republic of) No insurance coverage. Patients must pay all costs for fertility preservation treatment
themselves. The cost is approximately 2,000 to 3,000 USD for oocyte or embryo
cryopreservation. For ovarian tissue cryopreservation, only operation costs may be
partially covered by insurance. In the end, the total costs for ovarian tissue
cryopreservation are similar to oocyte or embryo cryopreservation.
$$$-$$$$
Turkey No insurance coverage. $$$$
Europe
Austria Reimbursement differs from province to province. Generally, storage is not covered,
which in Innsbruck amounts to 310 USD per year. Ovarian tissue cryopreservation is
sometimes reimbursed by insurance, but this differs among insurance companies.
Cryopreservation of oocytes and spermatozoa are not covered and must be entirely
funded by patients. IVF for the generation of blastocytes may be paid for by the IVF
Fund if the couple has an indication (pathospermia, endometriosis, tubal factor, or
PCO), but this is handled differently depending on the institution.
$$
Belgium Fertility preservation procedures are free to patients younger than 18 years because
techniques are still considered experimental for minors. Patients with cancer older
than 18 years pay a reduced price (compared with patients without cancer) of
approximately 560 USD out-of-pocket v several thousand USD. Embryo
cryopreservation is fully reimbursed in all cases. The Minister of Healthcare
announced in 2016 that partial reimbursement of fertility preservation procedures for
patients with cancer would begin in 2017.
0-$$
Denmark Insurance covers the cost of ovarian tissue cryopreservation. 0
France French social security covers all costs (whatever the technique used) for patients with
a medical indication for fertility preservation. Fertility preservation without medical
indication is not authorized.
0
Germany Insurance partially covers costs. $$
Poland No coverage. Cost to the patient is approximately 670 to 2,780 USD for all
cryopreservation procedures. Consultation and medical examinations are reimbursed
under the Polish National Health Service, but ART and cryopreservation procedures,
such as transplantation, are not covered. The cost of the medical consultation for
a patient interested in fertility-preserving methods is reimbursed on the basis of their
health insurance.
$$$-$$$$
(Continued on following page)
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TABLE 2. Regional Estimates of the Potential Out-of-Pocket Financial Burden of Fertility Preservation Procedures for Patients With Cancer (Continued)
Continent and Country Coverage of Fertility Preservation Procedures Rank of Cost to Patient
Portugal Consultations, medical examinations, technical procedures, and cryopreservation
procedures are all covered under the Portuguese National Health Service. Medication
is covered at 69%, so patients must pay for the other 31% (cost to the patient for
medication is approximately several hundred USD).
0-$$
Netherlands Most costs are reimbursed by insurance, but experimental procedures, such as
cryopreservation of ovarian tissue or testicular stem cells, is paid for by the hospital.
0
Russian Federation No coverage. The first 12months of tissue storage costs are approximately 220 USD. For
the second year on, costs are approximately 100 USD per year. Discounts are offered
for long-term storage. Adolescents younger than 25 years are covered by charities.
0-$$$
Spain Public insurance covers cryopreservation of eggs, sperm, and embryos as well as
a limited number of cycles of assisted reproduction. Because ovarian cortex and
immature testicular tissue cryopreservation are considered experimental procedures,
they are covered by research grants.
0
United Kingdom of Great Britain
and Northern Ireland
State coverage for most options (although some restrictions on access exist) and partial
research funding for experimental options (ovary and testis cryopreservation) are
available.
0
North America
Canada Varies greatly by province. In Quebec, fees for IVF procedures, cryopreservation, and
medication are all covered by the government insurance plan, including storage fees.
In other provinces, IVF is not government funded, but some provinces offer a tax
credit, and not-for-profit foundations offer some funding. As of December 21, 2015,
the Ontario government also started an Ontario Fertility Program, which covers egg
and sperm freezing for oncologic/medical need. However, in all other provinces in
Canada, no provincial health coverage of fertility preservation procedures exists.
0-$
Mexico No insurance coverage. Tissue collection costs are covered by the hospital. Some IVF
laboratories charge for tissue storage, whereas others may not. IVF laboratories
determine costs on an individual basis. Costs to the patient are generally high.
$$$$
Panama Costs are partially reimbursed by a private national foundation for fertility patients.
Medications are reimbursed by pharmacotherapeutic companies. Patients must pay
a small fee.
$$
United States Insurance may cover some of the costs of fertility preservation procedures, but copays
are usually significant. Public assistance does not cover any costs.
$$
Oceania
Australia Insurance will cover some costs toward day procedures, anesthesia, and egg and
embryo cryopreservation, depending on the level of patient coverage and on policy.
Fertility is an additional category for most insurance companies that must be selected,
or the policy has to be open for a specified time, depending on the insurance type. The
Australian hospitals surveyed cover the costs for fertility preservation procedures.
Storage costs vary. Recently, there have been new applications for oncofertility item
numbers (1) AMH testing before or after cancer treatment; (2) ovarian transposition;
(3) processing and handling ovarian cryopreservation, testicular cryopreservation,
and semen; and (4) psychological support during and after fertility preservation.
Outcomes are pending.
$$$$
South America
Argentina Insurance covers the cost of most fertility preservation procedures, especially for patients
with cancer.
0-$
Brazil No coverage. The approximate cost of egg cryopreservation is 3,500-4,500 USD (with
medication), embryo cryopreservation is approximately
4,500- 5,500 USD (with medication), ovarian tissue cryopreservation
is approximately 4,000 USD (including the surgery), and sperm cryopreservation is
approximately 400 USD. Costs vary by region as a result of tax disparities between
various states and populations with distant purchasing power. No coverage exists for
tissue storage as well. Cost for cryopreserved tissue storage is approximately 150USD,
with an annual maintenance cost of approximately 250 USD.
$$$$
(Continued on following page)
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time, or a lack of site-specific guidelines, especially with
regard to treating pediatric patients.8,16,17 Global strides
must still be made to educate oncologists about onco-
fertility, the fertility preservation options available to pa-
tients, and the importance of discussing fertility with
patients at the time of diagnosis.
To our knowledge, the costs and legal restrictions to care in
the field of oncofertility have never been systematically
identified or analyzed by region or center. This information
should be readily accessible to patients and providers.
Specifically, egg, sperm, and embryo donation often may
not be accessible and for this reason, not discussed as
a future option at the initial consultation because of fi-
nancial, cultural, and legal restraints. Specifically, the re-
spondents from the Banco de Sêmen do Rio de Janeiro in
Brazil stated that the lack of compensation for sperm do-
nors is a huge barrier to providing this service to their
patients. Cultural customs play a significant role in the
regulation of third-party assisted reproductive technologies,
which are explicitly observed in two surveyed countries,
Egypt and Tunisia. Both countries outlaw egg, sperm, and
embryo donation.18
Lack of insurance coverage poses a great barrier to patient
access to oncofertility care.19,20 Of note, insurance in
Tunisia only covers costs of fertility preservation procedures
in cases where a couple has demonstrated infertility. In-
fertility is difficult, if not impossible, for pediatric and un-
married patients to prove, which imposes an undue
financial challenge to this proportion of oncofertility pa-
tients. Costs for fertility preservation procedures in Tunisia
remain lower than at other sites, but only approximately
50% of patients follow through with procedures because of
the high cost of gonadotropins.
In the United States, a paradox exists about insurance
coverage of fertility preservation procedures. Insurance
generally covers the costs of iatrogenic conditions that
result from cancer treatment, such asmastectomy and wigs
for alopecia.21 However, despite the fact that infertility as
a result of cancer is iatrogenic, fertility preservation pro-
cedures are considered an exception and often are not
covered by government-subsidized national insurance or
private companies.21 Insurance companies require burden
of proof for infertility; therefore, couples must demonstrate
1 year of unsuccessful attempts to conceive before they
receive the diagnosis of infertility. This policy is un-
acceptable because fertility preservation addresses the
potential future infertility of currently fertile individuals.21
Changes in policy are needed to ensure that all iatrogenic
conditions after cancer treatment are covered by national
health insurance systems, and hopefully, private insurers
will follow suit.
As of 2016, 31 countries are part of the surveyed OC Global
Partners Network. This list is not exhaustive, and onco-
fertility practicing organizations in other countries were not
included in this analysis. That said, this study represents
a first attempt to quantify services in this emerging disci-
pline. Fertility management is complex and must take into
account culturally sensitive attitudes within each region of
the world, and reanalysis of the services provided is im-
portant as this field expands.
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TABLE 2. Regional Estimates of the Potential Out-of-Pocket Financial Burden of Fertility Preservation Procedures for Patients With Cancer (Continued)
Continent and Country Coverage of Fertility Preservation Procedures Rank of Cost to Patient
Chile Costs are partially covered. Insurance and public hospitals may cover some of the costs
of ovarian tissue collection. Ovarian tissue cryopreservation is covered by university
research grants. Sperm storage is fully paid for by public and private insurance.
Oocyte and embryo banking are not covered by insurance or public assistance. The
approximate cost of egg cryopreservation is 4,000 USD (with medication), whereas
embryo cryopreservation is approximately 5,000 USD (with medication).
$$$$
Peru No insurance coverage. Fertility preservation procedures for patients with cancer are just
starting to be offered, so at this point, patients are responsible for all costs. Starting fee
is approximately 1,500 USD for ovarian cryopreservation and an additional 600 USD
for ex vivo IVM if performed in parallel (both fees do not include the expenses related to
surgical procedures to remove the ovary). Cost is approximately 3,000 USD for
a regular IVM procedure (including embryo cryopreservation).
$$$
NOTE. The rank of cost to patient scale is as follows: 0, no out-of-pocket costs to patients; $, very little costs to patients (eg, only storage or small costs for
medications; range, 0-200 USD); $$, some costs to patients (range, 200-1,000 USD); $$$, great costs to patients (range, 1,000-3,000 USD); $$$$, no
coverage or steep costs that patients are generally responsible for (range, ≥ 3,000 USD).
Abbreviations: AMH, anti-Müllerian hormone; ART, assisted reproductive technology; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; IVM,
in vitro maturation; PCO, polycysticovarian syndrome; USD, US dollars.
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Speakers’ Bureau: UCB (I)
Travel, Accommodations, Expenses: Abbott Laboratories (I)
Johan Smitz
Speakers’ Bureau: Ferring Pharmaceuticals
Travel, Accommodations, Expenses: Ferring Pharmaceuticals
Maria T. Bourlon
Leadership: Medivation, Astellas Pharma
Honoraria: Medivation, Astellas Pharma
Speakers’ Bureau: Asofarma
Research Funding: Bristol-Myers Squibb
Travel, Accommodations, Expenses: Janssen Pharmaceuticals
Michel De Vos
Honoraria: Cook Medical
Research Funding: Cook Medical
Richard A. Anderson
Consulting or Advisory Role: Roche, HRA Pharma, NeRe Pharmaceuticals
Speakers’ Bureau: Roche, Beckman Coulter, IBSA Institut Biochimque
Research Funding: Ferring Pharmaceuticals
Travel, Accommodations, Expenses: IBSA Institut Biochimque
Roberto de A. Antunes
Consulting or Advisory Role: Merck Serono
Speakers’ Bureau: Merck Serono
Travel, Accommodations, Expenses: Merck Serono, MSD
Teresa Almeida-Santos
Consulting or Advisory Role: Merck, MSD
Research Funding: Merck
Teresa K. Woodruff
Research Funding: Ferring Pharmaceuticals (Inst)
No other potential conflicts of interest were reported.
Rashedi et al
340 © 2020 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 185.172.86.191 on April 6, 2020 from 185.172.086.191
Copyright © 2020 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
ACKNOWLEDGMENT
We thank all members of the OC Global Partners Network for their hard
work and dedication to oncofertility.
REFERENCES
1. Letourneau JM; Ebbel EE, Katz PP, et al: Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer.
Cancer 118:1710-1717, 2012
2. De Vos M, Smitz J, Woodruff TK: Fertility preservation in women with cancer. Lancet 384:1302-1310, 2014
3. Khrouf M, Bouyahia M, Berjeb K, et al: Perurethral transvesical route for oocyte retrieval: An old technique for a new indication. Fertil Steril 106:e129, 2016
(suppl 3)
4. Rashedi AS, de Roo SF, Ataman LM, et al: Survey of third-party parenting options associated with fertility preservation available to patients with cancer around
the globe. J Glob Oncol doi: 10.1200/JGO.2017.009944
5. Cunningham CT, Quan H, Hemmelgarn B, et al: Exploring physician specialist response rates to Web-based surveys. BMC Med Res Methodol 15:32, 2015
6. Gonçalves V, Sehovic I, Quinn G: Childbearing attitudes and decisions of young breast cancer survivors: A systematic review. HumReprod Update 20:279-292,
2014
7. Quinn GP, Vadaparampil ST, Lee JH, et al: Physician referral for fertility preservation in oncology patients: A national study of practice behaviors. J Clin Oncol 27:
5952-5957, 2009
8. Gonçalves V, Tarrier N, Quinn G: Thinking about white bears: Fertility issues in young breast cancer survivors. Patient Educ Couns 98:125-126, 2015
9. Freeman HP, Rodriguez RL: History and principles of patient navigation. Cancer 117:3539-3542, 2011 (suppl 15)
10. Ataman LM, Rodrigues JK, Marinho RM, et al: Creating a global community of practice for oncofertility. J Glob Oncol 2:83-96, 2016
11. Anazodo AC, Stern CJ, McLachlan RI, et al: A study protocol for the Australasian Oncofertility Registry: Monitoring referral patterns and the uptake, quality, and
complications of fertility preservation strategies in Australia and New Zealand. J Adolesc Young Adult Oncol 5:215-225, 2016
12. Ethics Committee of American Society for Reproductive Medicine: Fertility preservation and reproduction in patients facing gonadotoxic therapies: A committee
opinion. Fertil Steril 100:1224-1231, 2013
13. Loren AW, Mangu PB, Beck LN, et al: Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
J Clin Oncol 31:2500-2510, 2013
14. Razzano A, Revelli A, Delle Piane L, et al: Fertility preservation program before ovarotoxic oncostatic treatments: Role of the psychological support in managing
emotional aspects. Gynecol Endocrinol 30:822-824, 2014
15. Lee SJ, Schover LR, Partridge AH, et al: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:
2917-2931, 2006
16. McQuillan SK, Malenfant D, Jayasinghe YL, et al: Audit of current fertility preservation strategies used by individual pediatric oncologists throughout Australia
and New Zealand. J Pediatr Oncol 1:112-118, 2013
17. Knight S, Lorenzo A, Maloney AM, et al: An approach to fertility preservation in prepubertal and postpubertal females: A critical review of current literature.
Pediatr Blood Cancer 62:935-939, 2015
18. Center for Ethics and Law in Biomedicine: Annual Report. Budapest, Hungary, 2006
19. Berg Brigham K, Cadier B, Chevreul K: The diversity of regulation and public financing of IVF in Europe and its impact on utilization. Hum Reprod 28:666-675,
2013
20. Chambers GM, Sullivan EA, Ishihara O, et al: The economic impact of assisted reproductive technology: A review of selected developed countries. Fertil Steril
91:2281-2294, 2009
21. Campo-Engelstein L: Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol
28:1284-1286, 2010
n n n
Fertility Preservation Options for Patients With Cancer
JCO Global Oncology 341
Downloaded from ascopubs.org by 185.172.86.191 on April 6, 2020 from 185.172.086.191
Copyright © 2020 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
APPENDIX
TABLE A1. Respondent Organizations Listed by Continent and Country (organized according to the United Nations Statistics Division
geographical region groupings)
Continent and Country Respondent Organization
Africa
Egypt National Research Centre of Egypt (NRC)
Tunisia ART Center, Aziza Othmana Hospital of Tunis
Asia
China The First Affiliated Hospital of Nanjing Medical University
India Centre for Fertility Preservation, Kasturba Medical College, Manipal University
Iran (Islamic Republic of) Royan Institute
Japan Gifu University Graduate School of Medicine
Japan Society for Fertility Preservation (JSFP), St Marianna University School of
Medicine
Korea (Republic of) The Korean Society for Fertility Preservation (KSFP), Seoul National University
Bundang Hospital
Turkey Onkofertilite Turkiye
Europe
Austria Medical University of Innsbruck, Austria
Belgium Centrum voor Reproductieve Geneeskunde (CRG)
Denmark University Hospital of Copenhagen, Laboratory of Reproductive Biology
France Hôpital Jean-Verdier
Germany Medical Faculty of Cologne, Uniklinik Köln
Poland Oncofertility Poland, Jagiellonian University Medical College
Portugal Centro de Preservação da Fertilidade
Netherlands Radboud University Medical Center (Radboudumc)
Russian Federation Biologic Cryobank
Spain Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La
Fe
United Kingdom of Great Britain and Northern Ireland Edinburgh Fertility & Reproductive Endocrine Centre
North America
Canada McGill University Health Centre Reproductive Centre
Mexico Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran
Panama IVF Centro de Reproducción (IVFPANAMA)
United States Oncofertility Consortium, Northwestern Medicine
Oceania
Australia Royal Children’s Hospital Melbourne Australia
Sydney Children’s Hospital and Prince of Wales Hospital Sydney Australia
South America
Argentina Pregna Medicina Reproductiva
Brazil Banco de Sêmen do Rio de Janeiro
Clı́nica IVI São Paulo - Brasil
Fertilitat Centro de Medicina Reprodutiva
Fertility Preservation Research Group of the Federal University of São João Del
Rei
Fertipraxis Centro de Reprodução Humana
(Continued on following page)
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TABLE A1. Respondent Organizations Listed by Continent and Country (organized according to the United Nations Statistics Division
geographical region groupings) (Continued)
Continent and Country Respondent Organization
GENESIS - Centro de Assistência em Reprodução Humana
Hemoce - Centro de Hematologia e Hemoterapia do Ceará
Huntington Medicina Reprodutiva
Pró-Criar Medicina Reprodutiva
Universidade Federal de Minas Gerais Human Reproduction Laboratory
Vida Centro de Fertilidade
Chile Centro de Reproducción Humana - Universidad de Valparaı́so (CRH-ultraviolet)
Peru Centro de Estudios e Investigaciones en Biologı́a y Medicina Reproductiva -
BIOMER
NOTE. Composition of macro geographical (continental) regions, geographical subregions, and selected economic and other groupings
(United Nations Statistics Division, 2016. http://unstats.un.org/unsd/methods/m49/m49regin.htm).
TABLE A2. Survey Questions Asked of Oncofertility Consortium Global Partners Network Members and Other Experts in the Field and the
Corresponding Number of Respondent Organizations
Survey Question No. of Respondents
Is there a patient referral system at your center? If yes, does your center have a nurse navigator, social worker, or specific
oncofertility patient navigator? Please describe.
40
Do you provide psychological support to patients? If yes, please describe. 40
Does your center have a registry? 40
Which fertility preservation methods does your center offer to patients? See options given in Figure 1 40
Which methods are used most often? 40
Are there any services that are not offered due to cultural/religious boundaries or other restrictions? Please explain. 23
On average, how long does the process take from diagnosis to consult? 37
On average, how long does the process take from consult to fertility preservation? 37
On average, how long does the process take from fertility preservation to cancer treatment? 36
Please describe in detail the referral process at your center. Are the referral rates known? If so, what are the referral rates? 30
Does insurance cover the costs of fertility preservation procedures? If no, how do patients pay for fertility preservation
services and about how much do services cost? Do you feel that these costs may deter patients from seeking fertility
preservation procedures? Please be specific.
37
What barriers or challenges do you face at your center, if any? 37
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TABLE A3. Frequency and Percentage of Yes/No Responses
Survey Question Yes No Total Yes, % No, %
Is there a patient referral system at your center? 30 10 40 75 25
Does your center have a nurse navigator, social worker, or specific oncofertility
patient navigator?
9 25 34 27 73
Do you provide psychological support to patients? 30 10 40 75 25
Does your center have a registry? 35 5 40 87 13
Does insurance cover the costs of fertility preservation procedures? 11 26 37 30 70
Are there any services that are not offered due to cultural/religious boundaries or
other restrictions?
14 9 23 61 39
TABLE A4. Average Referral Times Indicated by Respondent Organizations
Type of Referral Time Frequency %
Time from cancer diagnosis to fertility preservation consultation. 1-2 days 14 35
3-5 days 9 23
1 week 8 20
2 weeks 4 10
. 3 weeks 2 5
No response 3 7
Time from fertility preservation consultation to fertility preservation. 1-2 days 9 23
3-5 days 9 23
1 week 7 17
2 weeks 8 20
. 3 weeks 4 10
No response 3 7
Time from fertility preservation to cancer treatment. 1-2 days 8 20
3-5 days 11 27
1 week 8 20
2 weeks 5 13
. 3 weeks 4 10
No response 4 10
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